Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.

We describe an overview of the trials that investigated docetaxel (CHAARTED and STAMPEDE-Docetaxel), abiraterone (LATTITUDE and STAMPEDE-Abiraterone), enzalutamide (ARCHES, ENZAMET), apalutamide (TITAN), and radiation to the primary (STAMPEDE-Radiation). DISCUSSION: The treatment of mHSPC is a complex topic, and treatment choice should be individualized. Patient preferences, cost, volume of disease, and side effect profiles are important in determining which option is the best for an individual patient. PMID: 31977388 [PubMed - in process]
Source: Cancer Journal - Category: Cancer & Oncology Authors: Tags: Cancer J Source Type: research